0000000000164641

AUTHOR

Hugo A. Katus

showing 7 related works from this author

2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (…

2017

2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) : Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries

medicine.medical_specialtyCarotid artery diseasebusiness.industryAtherosclerotic diseaseUpper extremity artery diseaseGuideline030204 cardiovascular system & hematologyVascular surgeryLower extremity artery diseaseMultisite artery diseasePeripheral Arterial Diseases3. Good health03 medical and health sciences0302 clinical medicineRenal artery diseaseInternal medicinePeripheral arterial diseasemedicineCardiologyMesenteric artery disease030212 general & internal medicineVertebral artery diseaseCardiology and Cardiovascular MedicinebusinessEuropean Heart Journal
researchProduct

Safety and efficacy of MitraClip™ therapy in patients with severely impaired left ventricular ejection fraction: results from the German transcathete…

2017

Aims The aim of the present study was to assess the safety and efficacy of percutaneous mitral valve repair using the MitraClip™ device in patients with severely reduced systolic left ventricular (LV) function. Methods and results Among 777 MitraClip™ implantations included in the German mitral valve registry, we identified 256 patients suffering from severely reduced LV function [ejection fraction (EF) 50%) and 280 patients presenting with an EF 30–50% prior to MitraClip™ therapy. High procedural success rates, low periprocedural complication rates, and low residual mitral regurgitation grades at discharge were achieved throughout all groups. In-hospital mortality was low and comparable in…

medicine.medical_specialtyMitral regurgitationEjection fractionbusiness.industryMortality rateMitraClip030204 cardiovascular system & hematologymedicine.disease3. Good healthSurgery03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureInternal medicineMitral valveHeart failuremedicineCardiology030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessComplicationPercutaneous Mitral Valve RepairEuropean Journal of Heart Failure
researchProduct

Bridge to Operation with the GPIIb/IIIa Inhibitor Abciximab in High-Risk Coronary Patients

2006

BACKGROUND Glycoprotein-IIb/IIIa inhibitors are now frequently used in the cardiological treatment of high-risk coronary patients even if the patient is considered suitable for surgical intervention. However, there is no consensus whether GPIIb/IIIa inhibitors should be stopped before operation because of an increased risk of bleeding or if surgery should even be delayed until the anticoagulating effect subsides. METHODS From June 2002 to August 2003 140 patients who had to undergo primary aorto-coronary bypass for ongoing myocardial ischemia were enrolled in the present study. The patients received either clopidogrel, aspirin and heparin or additionally abciximab until operation. RESULTS A…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyAbciximabMyocardial InfarctionHemodynamicsCoronary DiseasePlatelet Glycoprotein GPIIb-IIIa ComplexImmunoglobulin Fab FragmentsGpIIb/IIIaRisk FactorsInternal medicinemedicineAbciximabHumansProspective StudiesRegistriesCoronary Artery BypassAgedAspirinbusiness.industryIncidence (epidemiology)Antibodies MonoclonalHeparinMiddle AgedClopidogrelSurvival AnalysisHemostasis SurgicalTreatment OutcomeBridge (graph theory)Elective Surgical ProceduresCardiologyFemaleSurgeryCardiology and Cardiovascular MedicinebusinessBiomarkersPlatelet Aggregation InhibitorsFollow-Up Studiesmedicine.drugThe Thoracic and Cardiovascular Surgeon
researchProduct

Multicenter evaluation of a second-generation assay for cardiac troponin T.

1997

Abstract We report on the evaluation of the second-generation assay for cardiac troponin T (cTnT) on the Enzymun®system. This new assay is completely specific for the cardiac isoform of TnT, utilizing two cardiospecific monoclonal antibodies. The assay time is reduced to 45 min. The interassay precision shows a median CV of 5.5%; 20% interassay CV was found between 0.05 and 0.1 μg/L. The cardiosensitivity of the second-generation cTnT assay in patients with ischemic myocardial injury appears equivalent when compared with the first-generation assay. We found no falsely positive results in patients with skeletal muscle damage including multitraumas, surgery patients, and marathon runners who …

Gene isoformmedicine.medical_specialtyCardiac troponinHeart diseasemedicine.drug_classClinical BiochemistryMyocardial IschemiaMonoclonal antibodySensitivity and SpecificityTroponin complexTroponin TInternal medicinemedicineHumansMuscle SkeletalbiologyTroponin Tbusiness.industryMyocardiumBiochemistry (medical)Skeletal muscleReproducibility of Resultsmedicine.diseaseTroponinTroponinmedicine.anatomical_structureEndocrinologyCardiologybiology.proteinbusinessArtifactsTroponin CBiomarkersClinical chemistry
researchProduct

X-Linked Dilated Cardiomyopathy.

1995

We report on a family with a severe form of X-linked dilated cardiomyopathy (DCM). Two brothers, the elder requiring heart transplantation, and a maternal cousin presented elevated creatine kinase levels, increased right ventricular diameters and electrocardiographic abnormalities. All complained of exertional cramping myalgia, but none had muscle weakness or a pathological electromyogram. Muscle biopsies of these individuals revealed a mild myopathic picture with atrophic type I and hypertrophic type II fibers. Immunofluorescence using N- and C-terminal antibodies (dys-2, dys-3) against the dystrophin protein showed preserved, but reduced intensity of staining of the sarcolemmal membranes.…

AdultCardiomyopathy DilatedGenetic MarkersMaleX ChromosomeGenetic LinkageBiopsyMyosinsImmunofluorescencePolymerase Chain ReactionGeneral Biochemistry Genetics and Molecular BiologyDystrophinExonHistory and Philosophy of ScienceWestern blotmedicineHumansRNA MessengerMuscle SkeletalDNA PrimersSequence DeletionSouthern blotRecombination Geneticbiologymedicine.diagnostic_testMyocardiumGeneral NeuroscienceChromosome MappingDilated cardiomyopathyExonsmusculoskeletal systemmedicine.diseaseMolecular biologyPedigreeAlternative Splicingbiology.proteinFemaleCreatine kinaseLod ScoreAntibodyDystrophinAnnals of the New York Academy of Sciences
researchProduct

Posttranslationally modified proteins as mediators of sustained intestinal inflammation.

2006

Oxidative and carbonyl stress leads to generation of N(epsilon)-carboxymethyllysine-modified proteins (CML-mps), which are known to bind the receptor for advanced glycation end products (RAGE) and induce nuclear factor (NF)-kappaB-dependent proinflammatory gene expression. To determine the impact of CML-mps in vivo, RAGE-dependent sustained NF-kappaB activation was studied in resection gut specimens from patients with inflammatory bowel disease. Inflamed gut biopsy tissue demonstrated a significant up-regulation of RAGE and increased NF-kappaB activation. Protein extracts from the inflamed zones, but not from noninflamed resection borders, caused perpetuated NF-kappaB activation in cultured…

AdultCell ExtractsMaleReceptor for Advanced Glycation End ProductsInflammationBiologyInflammatory bowel diseasep38 Mitogen-Activated Protein KinasesPathology and Forensic MedicineProinflammatory cytokineRAGE (receptor)MiceGlycationhemic and lymphatic diseasesGene expressionmedicineAnimalsCalgranulin BHumansCalgranulin AIntestinal MucosaReceptors ImmunologicReceptorProtein Kinase InhibitorsMice KnockoutMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3LysineNF-kappa Bnutritional and metabolic diseasesEndothelial Cellsmedicine.diseaseNFKB1Inflammatory Bowel DiseasesIntestinesDisease Models AnimalImmunologyCancer researchFemalemedicine.symptomProtein Processing Post-TranslationalRegular ArticlesThe American journal of pathology
researchProduct

Guideline-adherence regarding critical time intervals in the German Chest Pain Unit registry

2020

Background: Since 2008, the German Cardiac Society certified 256 Chest Pain Units (CPUs). Little is known about adherence to recommended performance measures in patients with suspected acute coronary syndrome (ACS) presenting to CPUs. We investigated guideline-adherence regarding critical time intervals and selected performance measures in German Chest Pain Units. Methods: From 2008 to 2014, 23,804 consecutive patients with suspected ACS were prospectively enrolled in the Chest Pain Unit registry of the German Cardiac Society. Results: Median time from symptom onset to first medical contact was 2 h in patients with ST-elevation myocardial infarction (STEMI) and 4 h in patients with unstable…

MaleCritical timeMedizinische Fakultät » Universitätsklinikum Essen » Institut für PathophysiologieTime FactorsMedizin030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineChest painGermanElectrocardiography610 Medical sciences Medicine0302 clinical medicineGermanyProspective StudiesRegistries030212 general & internal medicineNon-ST Elevated Myocardial InfarctionGuideline adherenceGeneral MedicineMiddle AgedHospitalizationlanguageFemaleAcute coronary syndromeGuideline Adherencemedicine.symptomCardiology and Cardiovascular MedicineHospital UnitsChest Painmedicine.medical_specialtyAcute coronary syndromeguideline-adherence61003 medical and health sciencesPercutaneous Coronary Interventiontime intervalsmedicineHumansIn patientddc:610Angina Unstablecardiovascular diseasesAcute Coronary SyndromeAgedbusiness.industryUnstable anginamedicine.diseaseChest Pain Unitlanguage.human_languageEmergency medicineExercise TestST Elevation Myocardial InfarctionTomography X-Ray ComputedbusinessEuropean Heart Journal: Acute Cardiovascular Care
researchProduct